Background
Many dermatological topicals are available for human use and may be toxic to dogs and cats. No epidemiological studies have been performed in the US population on the use of dermatological topical prescription drugs, and their toxicosis to dogs and cats.
Objectives
Summarize the variety of dermatological topical prescriptions potentially used by pet owners in the United States (US), and describe the epidemiology of dog and cat exposures and toxicities.
Animals/Subjects
A dataset of 10,170 individuals from the National Health and Nutrition Examination Survey (NHANES) representative of 311,065,381 US residents. There were 61,169 dog and cat cases with exposure to dermatological topicals from the American Society for the Prevention of Cruelty to Animals (ASPCA) Animal Poison Control Center (APCC) database.
Methods and materials
Prescription medication data were analyzed from NHANES 2011–2014 survey respondents. The APCC database was searched for records of dermatological topical drug cases between January 2001 and January 2018.
Results
Prescription dermatological topical medications were used by 1.33 ± 0.21% of the US population. Dermatological topical products (177, veterinary and human) resulted in 61,169 exposure calls to the APCC. Clinical signs developed in 38% (22,910). A human‐labelled product was involved in 15% (3,463) with 74% (2,545) involving a prescription product.
Conclusions and clinical significance
Pets in households with humans receiving dermatological prescription topicals may be at risk for toxicosis. Multiple human‐labelled dermatological topicals can cause death or major illness to dogs and cats at low dosages. Increased public awareness, especially attention to home storage practices for human‐labelled dermatological topicals, may reduce the risk of exposure and toxicosis to dogs and cats.